77 related articles for article (PubMed ID: 4014106)
1. Marked prolongation in disappearance half-time of plasma cholecystokinin-octapeptide in patients with hepatic cirrhosis.
Kanayama S; Himeno S; Kurokawa M; Shinomura Y; Kuroshima T; Okuno M; Tsuji K; Higashimoto Y; Ikei N; Hashimura E
Am J Gastroenterol; 1985 Jul; 80(7):557-60. PubMed ID: 4014106
[TBL] [Abstract][Full Text] [Related]
2. Plasma cholecystokinin-octapeptide like immunoreactivity in patients with hepatic cirrhosis.
Kanayama S; Himeno S; Higashimoto Y; Yamasaki Y; Kitani T; Tarui S
Life Sci; 1987 Oct; 41(16):1915-20. PubMed ID: 3657391
[TBL] [Abstract][Full Text] [Related]
3. Plasma cholecystokinin responses after ingestion of liquid meal and intraduodenal infusion of fat, amino acids, or hydrochloric acid in man: analysis with region specific radioimmunoassay.
Himeno S; Tarui S; Kanayama S; Kuroshima T; Shinomura Y; Hayashi C; Tateishi K; Imagawa K; Hashimura E; Hamaoka T
Am J Gastroenterol; 1983 Nov; 78(11):703-7. PubMed ID: 6637957
[TBL] [Abstract][Full Text] [Related]
4. Heparin elimination in patients with liver cirrhosis.
Teien AN
Thromb Haemost; 1977 Oct; 38(3):701-6. PubMed ID: 579516
[TBL] [Abstract][Full Text] [Related]
5. Half-life time or clearance of indocyanine green in patients with liver disease.
Gilmore IT; Marigold JH; Thompson RP
Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
[TBL] [Abstract][Full Text] [Related]
6. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function.
Gerbes AL; Møller S; Gülberg V; Henriksen JH
Hepatology; 1995 Mar; 21(3):735-9. PubMed ID: 7875671
[TBL] [Abstract][Full Text] [Related]
7. Dipyrone metabolism in liver disease.
Zylber-Katz E; Caraco Y; Granit L; Levy M
Clin Pharmacol Ther; 1995 Aug; 58(2):198-209. PubMed ID: 7648770
[TBL] [Abstract][Full Text] [Related]
8. Cholecystokinin cleavage to cholecystokinin-octapeptide in vivo and in vitro: accelerated cleavage in acute pancreatitis.
Springer CJ; Calam J
Gastroenterology; 1988 Jul; 95(1):143-50. PubMed ID: 2453390
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of somatostatin on cholecystokinin octapeptide induced bile regurgitation under stress: ionic and molecular mechanisms.
Si X; Huang L; Luo H; Shi R
Regul Pept; 2009 Aug; 156(1-3):34-41. PubMed ID: 19445970
[TBL] [Abstract][Full Text] [Related]
10. Impairment of citrate metabolism in acute hepatic failure.
Apsner R; Schwarzenhofer M; Derfler K; Zauner C; Ratheiser K; Kranz A
Wien Klin Wochenschr; 1997 Feb; 109(4):123-7. PubMed ID: 9076929
[TBL] [Abstract][Full Text] [Related]
11. Serum leptin levels in patients with nonalcoholic chronic liver disease.
Nakamuta M; Tada S; Uchimura K; Enjoji M; Kinukawa N; Iwamoto H; Sugimoto R; Shimada M; Ohashi M; Sugimachi K; Nawata H
Hepatogastroenterology; 2001; 48(38):527-32. PubMed ID: 11379347
[TBL] [Abstract][Full Text] [Related]
12. Normal metabolism of morphine in cirrhosis.
Patwardhan RV; Johnson RF; Hoyumpa A; Sheehan JJ; Desmond PV; Wilkinson GR; Branch RA; Schenker S
Gastroenterology; 1981 Dec; 81(6):1006-11. PubMed ID: 7286578
[TBL] [Abstract][Full Text] [Related]
13. Increased thromboxane metabolites excretion in liver cirrhosis.
Davì G; Ferro D; Basili S; Iuliano L; Camastra C; Giammarresi C; Santarone S; Rocca B; Landolfi R; Ciabattoni G; Cordova C; Violi F
Thromb Haemost; 1998 Apr; 79(4):747-51. PubMed ID: 9569186
[TBL] [Abstract][Full Text] [Related]
14. Disappearance rates of plasma growth hormone after intravenous somatostatin in renal and liver disease.
Pimstone BL; Le Roith D; Epstein S; Kronheim S
J Clin Endocrinol Metab; 1975 Aug; 41(2):392-3. PubMed ID: 1159052
[TBL] [Abstract][Full Text] [Related]
15. Enhanced renal clearance of uric acid in hepatic cirrhosis.
Higuchi T; Nakamura T; Uchino H
Isr J Med Sci; 1981 Nov; 17(11):1015-8. PubMed ID: 7319788
[TBL] [Abstract][Full Text] [Related]
16. [Effect of renal and liver failure on blood levels of vitamin A, its precursor (beta-carotene) and its carrier proteins (prealbumin and retinol binding protein)].
Adoncecchi L; Marrocco W; Suraci C; Pecora P; Gallinella B; Porrà R; Cavina G
Boll Soc Ital Biol Sper; 1984 Apr; 60(4):881-6. PubMed ID: 6539619
[TBL] [Abstract][Full Text] [Related]
17. [Hepatic clearance of 99mTc-p-butyl HIDA in liver diseases. Correlations with routine hematochemical parameters of liver function].
Custro N; De Francisci MC; Patanella I; Scafidi V; Indovina I
Minerva Med; 1984 Nov; 75(42):2527-32. PubMed ID: 6083507
[TBL] [Abstract][Full Text] [Related]
18. [Vitamin D3 level and age. Changes in the 1,25-dihydroxycholecalciferol level in various age groups in normal persons, in patients with osteoporosis, renal failure and liver cirrhosis].
Weiss H; Rest J; Limbach HJ
Med Klin (Munich); 1988 Oct; 83(20):660-6. PubMed ID: 3226368
[No Abstract] [Full Text] [Related]
19. Acute phase response after liver transplantation for fulminant hepatic failure and cirrhosis.
Izumi S; Hughes RD; Langley PG; Pernambuco JR; Williams R
Transpl Int; 1995; 8(5):340-5. PubMed ID: 7576014
[TBL] [Abstract][Full Text] [Related]
20. [Clearance concept applied to pharmacokinetics: 2. Experience with tolamolol (beta-blocking agent) in renal insufficiency (author's transl)].
Balant L; Gorgia A; Marmy A; Tschopp JM
Nephrologie; 1980; 1(4):177-82. PubMed ID: 6895408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
